CircRNA_102272 Promotes Cisplatin-Resistance in Hepatocellular Carcinoma by Decreasing MiR-326 Targeting of RUNX2

BACKGROUND: Hepatocellular carcinoma (HCC) is the leading cause of tumor-associated death in males and females worldwide. HCC is mostly diagnosed at advanced stages and the chemotherapeutic cisplatin is one of the major therapeutic options in the treatment of patients with treating advanced HCC. Des...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Yonghai, Zhang, Ying, Hao, Lina, Nie, Zhenwang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732977/
https://www.ncbi.nlm.nih.gov/pubmed/33324096
http://dx.doi.org/10.2147/CMAR.S258230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732977/
https://www.ncbi.nlm.nih.gov/pubmed/33324096
http://dx.doi.org/10.2147/CMAR.S258230

Ejemplares similares